We are live on
!
Find out more
PC
Polar Capital Portfolio holdings
AUM
$13.5B
1-Year Est. Return
55.9%
This Fund
S&P 500
This Quarter
Est. Return
-13.72%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$9.35B
AUM Growth
-$2.4B
(-20%)
Cap. Flow
-$757M
Cap. Flow
% of AUM
-8.1%
Top 10 Holdings %
Top 10 Hldgs %
23.15%
Holding
300
New
33
Increased
109
Reduced
94
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Danaher
DHR
|
+$66.5M |
| 2 |
Berkshire Hathaway Class B
BRK.B
|
+$62.4M |
| 3 |
Thermo Fisher Scientific
TMO
|
+$53.8M |
| 4 |
Arista Networks
ANET
|
+$47M |
| 5 |
Boston Scientific
BSX
|
+$45.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$112M |
| 2 |
Amgen
AMGN
|
+$102M |
| 3 |
Apple
AAPL
|
+$102M |
| 4 |
ATVI
Activision Blizzard
ATVI
|
+$72.8M |
| 5 |
Flex
FLEX
|
+$70.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.47% |
| 2 | Financials | 23.51% |
| 3 | Healthcare | 21.25% |
| 4 | Communication Services | 7.66% |
| 5 | Consumer Discretionary | 6.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KALV
226
DELISTED
KalVista Pharmaceuticals
KALV
| $1.56M | 0.02% |
+78,900
| New | +$1.59M |
|
|
DESP
227
DELISTED
Despegar.com
DESP
| $1.4M | 0.02% |
113,097
| – | – |
|
|
MIXT
228
DELISTED
MIX TELEMATICS LIMITED
MIXT
| $1.14M | 0.01% |
72,786
-101,168
| -58% | -$1.62M |
|
|
MTLS
229
Materialise
MTLS
$373M
| $1.1M | 0.01% |
55,107
-165,898
| -75% | -$2.41M |
|
|
VRNA
230
DELISTED
Verona Pharma
VRNA
| $965K | 0.01% |
100,000
| – | – |
|
|
IMMP
231
Immutep
IMMP
$57M
| $920K | 0.01% |
500,000
+254,302
| +104% | +$710K |
|
|
VIVE
232
DELISTED
VIVEVE MED INC
VIVE
| $748K | 0.01% |
712
-186
| -21% | -$447K |
|
|
JOBS
233
DELISTED
51job Inc
JOBS
| $723K | 0.01% |
11,572
+619
| +6% | +$39.6K |
|
234
Esquire Financial Holdings
ESQ
$1.1B
| $653K | 0.01% |
30,085
-6,095
| -17% | -$145K |
|
|
VNET
235
VNET Group
VNET
$1.92B
| $611K | 0.01% |
70,667
+1,882
| +3% | +$18.6K |
|
236
NetEase
NTES
$81.5B
| $610K | 0.01% |
12,970
+6,760
| +109% | +$305K |
|
|
FENG
237
Phoenix New Media
FENG
$17.4M
| $605K | 0.01% |
31,486
+8,106
| +35% | +$166K |
|
238
NovaGold Resources
NG
$2.55B
| $501K | 0.01% |
126,946
| – | – |
|
239
Summit Therapeutics
SMMT
$10B
| $403K | ﹤0.01% |
350,000
| – | – |
|
240
Texas Capital Bancshares
TCBI
$4.29B
| $310K | ﹤0.01% |
+6,065
| New | +$382K |
|
241
Enterprise Financial Services Corp
EFSC
$2.42B
| $297K | ﹤0.01% |
7,884
-1,787
| -18% | -$79.5K |
|
242
Goldman Sachs
GS
$305B
| $273K | ﹤0.01% |
1,637
-1,802
| -52% | -$364K |
|
243
CALL
Meta Platforms (Facebook)
META
$1.51T
| $16K | ﹤0.01% |
+8,000
| New | +$1.16M |
|
244
CALL
Advanced Micro Devices
AMD
$741B
| $15K | ﹤0.01% |
15,450
| – | – |
|
|
245
CALL
Apple
AAPL
$4.99T
| $7K | ﹤0.01% |
29,200
| – | – |
|
|
FENG
246
CALL
Phoenix New Media
FENG
$17.4M
| $2K | ﹤0.01% |
+62
| New | +$1.27K |
|
247
Agilent Technologies
A
$39.7B
| – | – |
-778,000
| Closed | -$54.9M |
|
248
Aclaris Therapeutics
ACRS
$744M
| – | – |
-1,443,920
| Closed | -$21M |
|
249
Analog Devices
ADI
$178B
| – | – |
-27,688
| Closed | -$2.56M |
|
|
AMRN
250
Amarin Corp
AMRN
$293M
| – | – |
-69,589
| Closed | -$22.6M |
|
Similar funds
ECM
FAAS
WAM
FS
NIMC
TI
VIM
PS
Polar Capital's Q4 2018 Portfolio in Review
As of Q4 2018, Polar Capital held 300 positions worth $9.35B, down 20% from $11.8B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Polar Capital withdrew a net $757M in Q4 2018, closing 43 positions and reducing 94 holdings. Its most notable exit was Activision Blizzard, an estimated $72.8M position sold in full.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 25% a quarter earlier, followed by Financials and Healthcare.
Against the trend, Polar Capital opened a new position in Boston Scientific worth $44.2M.
- Polar Capital's largest Q4 2018 buy was Boston Scientific: 1,250,000 shares worth $44.2M.
- Polar Capital added most to Danaher in Q4 2018, an estimated $66.5M increase.
- Polar Capital's biggest Q4 2018 reduction was Merck, cutting an estimated $112M.
- Polar Capital fully exited Activision Blizzard in Q4 2018, selling an estimated $72.8M.
- Polar Capital's ten largest holdings make up 23% of its $9.35B portfolio in Q4 2018.
- Polar Capital opened 33 new positions and closed 43 in Q4 2018.
- Polar Capital's portfolio value fell 20% quarter-over-quarter to $9.35B.
Based on Polar Capital's 13F filing for Q4 2018, filed 14 Feb 2019.